-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$9.25-53.73% Downside
ADMA Biologics, Inc. Frequently Asked Questions
-
What analysts cover ADMA Biologics, Inc.?
ADMA Biologics, Inc. has been rated by research analysts at Mizuho Securities, H.C. Wainwright in the past 90 days.